# PulmoBioMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pulmobiomed

- Industry: Biotechnology
- Headquarters: Newcastle upon Tyne, UK
- Website: www.pulmobiomed.com/
- Total disclosed funding: $1.9M
- Latest round: Seed (Nov 13, 2023)
- Investors on record: 3

## About

Founded in 2020 and based in the UK, PulmoBioMed Ltd., operates as a biotechnology research company focused on developing breath condensate and aerosol sampling technology to help in disease and environmental diagnostics. In February 2024, PulmoBioMed Ltd. received GBP 0.07 million in grant funding from Innovate UK. As of 2024, the company is led by its CEO, Sterghios A. Moschos.

The company provides clinicians and researchers with diagnostic-grade samples without the need for invasive procedures like bronchoalveolar lavage (BAL) or sputum samples.

The company’s product, PBM-Hale™, non-invasive sampler of the deep lung designed to collect exhaled gas, consists of a disposable mouthpiece and a sealed sampling unit, along with optional accessories like a condenser and a facemask for customized sampling process control.

The company plans to use the February 2024 funding to develop a cost-effective manufacturing process, scale up production, register its product in the US, and develop clinical utility evidence for asthma diagnosis.

## Funding rounds

- Seed, Nov 13, 2023, $1.9M — Mercia Asset Management, Northumbria University, SFC Capital

## Investors

- Mercia Asset Management (https://capitalatlas.ai/funds/mercia-asset-management) — Seed
- Northumbria University — Seed
- SFC Capital (https://capitalatlas.ai/funds/sfc-capital) — Seed